Резистентность к аспирину: обзор современных представлений о возможных механизмах

  • В. В. Джаши Московская Медицинская Академия им. И.М.Сеченова, Москва, Россия
Ключевые слова: антиагрегантная терапия, аспирин, механизм резистентности, резистентность к аспирину

Аннотация

Антиагрегантная терапия является одной из основ лечения атеротромботических осложнений сердечно¬сосудистых заболеваний, а аспирин - самым назначаемым препаратом из этой группы. Несмотря на его до¬казанную эффективность, многие пациенты, принимающие аспирин, испытывать сердечно-сосудистые ка¬тастрофы. Механизм резистентности до сих пор точно не изучен, однако известно, что в него могут быть вовлечены различные факторы, начиная от плохой приверженности к лечению, и заканчивая генетическим полиморфизмом гликопротеиновых рецепторов тромбоцитов. Очевидно, что необходимы дальнейшие иссле¬дования на эту тему, так как знание точного механизма резистентности поможет оптимизировать тера¬пию и предотвратить большое количество атеротромботических осложнений.

Литература

Antiplatelet Trialists’ collaboration. Collaborative overview of randomized trials of Antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged Antiplatelet therapy in various categories of patients. BMJ.1994; 308:81-106.

ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction:ISIS-2. Lancet. 1988;2:349-360.

Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomized trials of Antiplatelet ther¬apy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002;324,71-86.

Grotemeyer KH, Scharafinski HW, Husstedt IW. Two- year follow-up of aspirin responder and aspirin non¬responders. A pilot-study including 180 post-stroke patients. Thromb Res. 1993;71(5):397-403.

Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol. 2003;250 (1):63-6.

Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, et al. Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78(3):1003-7.

Gum PA, Kottke-Marchant K, Welsh PA, White J, To¬pol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable pa¬tients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-5.

Christopher P. Martin, Robert L. Talbert. Aspirin Resis¬tance: An evaluation of Current Evidence and Measure¬ment Methods. Pharmacotherapy. 2005; 25(7):942-953.

Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367(9510):606-17.

Topol EJ, Easton D, Harrington RA, Amarenco P, Califf RM, Graffagnino C, Davis S, Diener H-C, Ferguson J, Fitzgerald D, Granett J, Shuaib A, Koudstaal PJ, Ther¬oux P, Van de Werf F, Sigmon K, Pieper K, Vallee M, Willerson JT. Randomized, double-blind, placebo- controlled, international trial of the oral IIb/IIIa antago¬nist lotrafiban in coronary and cerebrovascular disease. Circulation 2003;108:399-406.

Bhatt DL, Chew DP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery .Circulation 2001;103:363-368.

Chen W-H, Lee PY, Ng W, Yat-Yin Kwok J, Cheng X, Tse HF, Lau CP.Prevalence, profile, and predictors of aspirin resistance measured by the Ultegra rapid platelet function assay-ASA in patients with coronary artery disease. J Am Coll Cardiol 2005;45:382A.

Bhatt DL, Topol EJ. Antiplatelet and anticoagulant ther¬apy in the secondary prevention of ischemic heart dis¬ease. Med Clin North Am 2000;84:163-179.

J.C.Hostetter, D.L.Bhatt. The expanding role of Anti¬platelet agents in coronary artery disease. Minerva Car- dioangiol 2003; 51:531-46.

MacDonald TM, Wei L. Effect of ibuprofen on cardio- protecive effect os aspirin. Lancet 2003; 361:573-4.

Hurlen M, Seljeflot I, Arnesen H. Increased platelet aggregability during exercise in patients with previous myocardial infarction. Lack of inhibition by aspirin. Thromb Res. 2000;99(5):487-94.

Pulcinelli FM, Pignatelli P, Celestini A, Riondino S, Gazzaniga PP, Violi F. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. J Am Coll Cardiol. 2004;43(6):979-84.

Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterio- scler Thromb Vasc Biol. 2004;24(2):246-55.

Newman PJ, Derbes RS, Aster RH. The human platelet alloantigens PLA1 and PLA2 are associated with a leu- cine3 3/proline33 amino acid polymorphism in mem¬brane glycoprotein IIIa, and are distinguishable by DNA typing. J Clin Invest 1989;83:778-81.

Helgason CM et al. (1994) Development of aspirin re¬sistance in persons with previous ischemic stroke. Stroke 25: 2331-2336.

Cotter G, Shemesh E, Zehavi M, Dinur I, Rudnick A, Milo O, et al. Lack of aspirin effect: aspirin resistance or resistance to taking aspirin? Am Heart J. 2004;147 (2):293-300.

Ray WA, Stein CM, Hall K, Daugherty JR, Griffin MR. Nonsteroidal anti-inflammatory drugs and risk of seri¬ous coronary heart disease: an observational cohort study. Lancet 2002;359:118-23.

Livio V, Delmaschio A, Cerletti C, deGaetano G. Indo- methacin prevents long-lasting inhibitory effects of aspirin on human platelet cyclooxygenase. Prostagland¬ins 1982; 23:787-96.

Cipollone F, Rocca B, Patrono C. Ciclooxygenase-2 expression and inhibition in atherothrombosis. Arterio- scler Thromb Vasc Biol. 2004;24(2):246-55.

Patrono C, Coller B, Dalen JE, FitzGerald GA, Fuster V, Gent M, et al. Platelet-active drugs: the relationships among dose, effectiveness, and side effects. Chest. 2001;119(1 suppl.):39S-63S.

Zimmerman N, Wenk A, Kim U, et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003;108:542-7.

Kawasaki T, Ozeki Y, Igawa T, Kambayashi J. In¬creased platelet sensitivity to collagen in individuals resistant to low-dose aspirin. Stroke 2000;31:591-5.

Weber AA, Zimmerman KC, Meyer-Kirchrath J, Schoer K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet 1999;353:900.

Опубликован
2018-05-31
Как цитировать
Джаши, В. (2018). Резистентность к аспирину: обзор современных представлений о возможных механизмах. Бюллетень международной научной хирургической ассоциации, 2(2-3), 45-48. извлечено от http://surgjournal.ru/index.php/BISSA/article/view/202
Раздел
Оригинальные статьи